Add to ORKGResults of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patient
BackgroundProphylactic factor replacement in patients with hemophilia B improves outcomes but requir...
This is the peer reviewed version of the following article:Volkers, P, Hanschmann, K‐M, Calvez, T, e...
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and m...
comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and...
The development of a new generation of coagulation factors with improved pharmacokinetic profile wil...
ABSTRACTRecombinant fusion protein linking recombinant coagulation factor IX with recombinant albumi...
and caregivers ’ perspectives on stability of factor VIII products for haemophilia A: a web-based st...
International audienceIntroduction: A phase 3b extension study evaluated the long-term safety and ef...
International audienceIntroduction: A phase 3b extension study evaluated the long-term safety and ef...
The Author(s) 2014. This article is published with open access at Springerlink.com Background and Ob...
Safety and efficacy of turoctocog alfa (NovoEight) during surgery in patients with haemophilia A: re...
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different...
(rFVIIa) is approved for use in controlling bleeding epi-sodes in people with hemophilia who have de...
Steven PipeDepartment of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI...
Aims: Prophylaxis with standard-acting recombinant factor IX (rFIX) in hemophilia B patients require...
BackgroundProphylactic factor replacement in patients with hemophilia B improves outcomes but requir...
This is the peer reviewed version of the following article:Volkers, P, Hanschmann, K‐M, Calvez, T, e...
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and m...
comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and...
The development of a new generation of coagulation factors with improved pharmacokinetic profile wil...
ABSTRACTRecombinant fusion protein linking recombinant coagulation factor IX with recombinant albumi...
and caregivers ’ perspectives on stability of factor VIII products for haemophilia A: a web-based st...
International audienceIntroduction: A phase 3b extension study evaluated the long-term safety and ef...
International audienceIntroduction: A phase 3b extension study evaluated the long-term safety and ef...
The Author(s) 2014. This article is published with open access at Springerlink.com Background and Ob...
Safety and efficacy of turoctocog alfa (NovoEight) during surgery in patients with haemophilia A: re...
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different...
(rFVIIa) is approved for use in controlling bleeding epi-sodes in people with hemophilia who have de...
Steven PipeDepartment of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI...
Aims: Prophylaxis with standard-acting recombinant factor IX (rFIX) in hemophilia B patients require...
BackgroundProphylactic factor replacement in patients with hemophilia B improves outcomes but requir...
This is the peer reviewed version of the following article:Volkers, P, Hanschmann, K‐M, Calvez, T, e...
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and m...
.svg%3Fwidth%3D300&w=3840&q=75)